AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Acumen Pharmaceuticals Inc (NASDAQ:ABOS)
2.29 USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | 2.29 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 3.600/0.959 |
| EBITDA (in USD) | -123.774M |
| PE Ratio | -- |
| Volume | 334530 |
| Diluted Eps TTM | -2.00 |
| Total Assets (in USD) | 122.833M |
|---|---|
| Total Liabilities (in USD) | 52.403M |
| Revenue TTM (in USD) | 0.329M |
| Cash (in USD) | 53.989M |
| Market Cap (in USD) | 205.084 M |
| Revenue Per Share TTM | 0.033 |
| Gross Profit TTM (in USD) | -104.885M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Employees: 60
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Daniel J. O'Connell M.B.A. | CEO, Pres & Director | 1971 |
| 2. | Mr. Matt Zuga | CFO, Chief Bus. Officer & Corp. Sec. | NA |
| 3. | Dr. Eric Siemers M.D. | Chief Medical Officer | 1955 |
| 4. | Mr. Russell Barton M.S. | Chief Operating Officer | 1959 |
| 5. | Mr. Derek M. Meisner Esq., J.D. | Chief Legal Officer | 1971 |
| 6. | Ms. Robyn Moxon M.A. | Mang. of Corp. & Clinical Communications | NA |
| 7. | Ms. Julie Bockenstette | Exec. VP & Head of HR | NA |
| 8. | Ms. Siew Tin Gan M.S. | Assistant VP & Head of Clinical Operations | NA |
| 9. | Ms. Janice Hitchcock | VP & Head of Regulatory Affairs | NA |
| 10. | Ms. Liean Schenck M.S. | VP & Head of CMC | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.750 4.167% | 43.09 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.780 4.216% | 43.8 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+13.400 3.128% | 434.95 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+9.780 1.580% | 628.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -121.335M | -102.329M | -52.371M | -42.856M | -100.606M |
| Minority Interest | - | - | - | - | - |
| Net Income | -121.335M | -102.329M | -52.371M | -40.475M | -181.679M |
| Selling General Administrative | 18.947M | 20.219M | 18.82M | 12.876M | 7.279M |
| Gross Profit | -0.184M | -0.178M | -42.318M | - | - |
| Reconciled Depreciation | 0.184M | 0.178M | 0.194M | 0.169M | 0.004M |
| Ebit | - | -98.261M | -51.79M | -45.237M | 61.573M |
| Ebitda | -123.832M | -98.083M | -51.606M | -45.068M | 61.577M |
| Depreciation And Amortization | - | 0.178M | 0.184M | 0.169M | 0.004M |
| Operating Income | -123.832M | -114.017M | -61.138M | -45.237M | 61.573M |
| Other Operating Expenses | 123.832M | 114.017M | 61.138M | 45.237M | 19.584M |
| Interest Expense | 4.224M | 4.068M | 0.581M | 2.381M | 81.022M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 7.447M | 14.317M | 8.232M | 2.392M | 0.084M |
| Net Interest Income | 3.223M | 10.249M | 8.232M | 2.392M | 0.084M |
| Income Tax Expense | - | - | - | -2.381M | 81.073M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 123.832M | 114.017M | 61.138M | 45.237M | 19.584M |
| Cost Of Revenue | 0.184M | 0.178M | 42.318M | - | - |
| Total Other Income Expense Net | 2.497M | 11.688M | 8.767M | 2.381M | -162.179M |
| Net Income From Continuing Ops | -121.335M | -102.329M | -48.74M | -42.856M | -100.606M |
| Net Income Applicable To Common Shares | - | - | - | -42.856M | -100.606M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 122.833M | 238.992M | 310.125M | 196.587M | 230.33M |
| Intangible Assets | 0.029M | 0.075M | - | - | - |
| Other Current Assets | 4.762M | 6.59M | 2.868M | 2.724M | 4.424M |
| Total Liab | 52.403M | 57.176M | 43.152M | 7.812M | 5.147M |
| Total Stockholder Equity | 70.43M | 181.816M | 266.973M | 188.775M | 225.183M |
| Other Current Liab | 20.538M | 21.826M | 10.726M | 6.067M | 4.059M |
| Common Stock | 0.006M | 0.006M | 0.006M | 0.004M | 0.004M |
| Capital Stock | 0.006M | 0.006M | 0.006M | 0.004M | 0.004M |
| Retained Earnings | -446.462M | -325.127M | -222.798M | -170.427M | -127.571M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 0M | 0.151M | 0.014M |
| Cash | 53.989M | 35.627M | 66.886M | 130.101M | 122.162M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 30.007M | 27.607M | 12.971M | 7.812M | 5.147M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -22.678M | -5.925M | -35.839M | -129.996M | -122.162M |
| Short Term Debt | 8.915M | 0.133M | 0.866M | 0.105M | 0.139M |
| Short Long Term Debt | 8.765M | - | - | - | - |
| Short Long Term Debt Total | 31.311M | 29.702M | 31.047M | 0.105M | 0.201M |
| Other Stockholder Equity | 516.803M | 506.985M | 489.453M | 359.949M | 122.651M |
| Property Plant Equipment | - | - | - | 0.165M | 0.036M |
| Total Current Assets | 122.252M | 178.306M | 246.615M | 180.329M | 198.661M |
| Long Term Investments | 0M | 59.968M | 62.553M | 15.837M | 31.619M |
| Short Term Investments | 62.876M | 135.93M | 176.636M | 47.504M | 72.075M |
| Net Receivables | 0.625M | 0.398M | 0.225M | 0.105M | 0.096M |
| Long Term Debt | 22.396M | 28.449M | 27.337M | - | - |
| Inventory | - | 0.159M | 0M | 0.199M | 0.083M |
| Accounts Payable | 0.554M | 5.648M | 1.379M | 1.64M | 1.088M |
| Accumulated Other Comprehensive Income | 0.083M | -0.048M | 0.312M | -0.751M | -0.231M |
| Non Currrent Assets Other | 0.581M | 0.379M | 0.221M | 0.151M | 0.014M |
| Non Current Assets Total | 0.581M | 60.686M | 63.51M | 16.258M | 31.669M |
| Capital Lease Obligations | 0.15M | 0.283M | 1.15M | 0.105M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 134.021M | 48.027M | -143.284M | 39.346M | -104.08M |
| Total Cashflows From Investing Activities | 133.933M | 48.027M | -171.671M | 39.185M | -104.12M |
| Total Cash From Financing Activities | -0.034M | 6.928M | 151.753M | 3.907M | 200.466M |
| Net Income | -121.335M | -102.329M | -52.371M | -42.856M | -100.606M |
| Change In Cash | 18.361M | -31.26M | -62.982M | 7.939M | 78.385M |
| Begin Period Cash Flow | 35.859M | 67.119M | 130.101M | 122.162M | 43.777M |
| End Period Cash Flow | 54.22M | 35.859M | 67.119M | 130.101M | 122.162M |
| Total Cash From Operating Activities | -115.538M | -86.215M | -43.064M | -35.153M | -17.961M |
| Depreciation | -0.751M | 0.178M | 0.184M | 0.169M | 0.004M |
| Other Cashflows From Investing Activities | - | - | 0.003M | - | - |
| Dividends Paid | - | 0M | 0M | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | -0.073M | -0.041M | 0M | 3.907M | 170.435M |
| Other Cashflows From Financing Activities | - | -0.23M | -0.151M | 0.115M | 31.91M |
| Capital Expenditures | 0.088M | 0.016M | 0.021M | 0.161M | 0.04M |
| Change In Working Capital | -5.119M | 11.653M | 3.866M | 3.986M | 0.298M |
| Other Non Cash Items | 1.815M | -5.352M | -0.888M | 0.487M | 81.266M |
| Free Cash Flow | -115.626M | -86.231M | -43.085M | -35.314M | -18.001M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Franklin Biotechnology Discv A(acc)USD | 2 months ago | 1861341 |
| 2. | Fidelity Select Health Care | 3 months ago | 1140000 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 1118322 |
| 4. | Franklin Biotechnology Discovery A | 2 months ago | 826400 |
| 5. | Fidelity Advisor Health Care I | 3 months ago | 700000 |
| 6. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 356155 |
| 7. | Fidelity VIP Health Care Initial | 3 months ago | 180000 |
| 8. | Fidelity Extended Market Index | 3 months ago | 175512 |
| 9. | Vifag 2002 SICAV | 3 months ago | 100000 |
| 10. | A4Investments SICAV SIF ACCI IlanaA2EURH | 2 months ago | 100000 |
| 11. | iShares Micro-Cap ETF | 2 months ago | 96480 |
| 12. | Bridgeway Ultra-Small Company Market | 5 months ago | 81871 |
| 13. | Bridgeway Ultra-Small Company | 5 months ago | 75000 |
| 14. | Extended Equity Market Fund B | 5 months ago | 65874 |
| 15. | Extended Equity Market Fund E | 5 months ago | 65874 |
| 16. | Blackrock Extended Mkt Fund CF | 3 months ago | 65874 |
| 17. | Fidelity Nasdaq Composite Index | 3 months ago | 64344 |
| 18. | Fidelity Total Market Index | 3 months ago | 59602 |
| 19. | Extended Equity Market Fund K | 2 months ago | 56090 |
| 20. | Fidelity Series Total Market Index | 3 months ago | 45873 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Bank of America Corp | 8 months ago | 213729 |
| 2. | RA Capital Management, LLC | 5 months ago | 14932063 |
| 3. | Sands Capital Ventures, LLC | 5 months ago | 3417075 |
| 4. | Franklin Resources Inc | 8 months ago | 2305096 |
| 5. | FMR Inc | 5 months ago | 2027497 |
| 6. | Vanguard Group Inc | 5 months ago | 1653772 |
| 7. | Knollwood Investment Advisory LLC | 5 months ago | 1628510 |
| 8. | Alyeska Investment Group, L.P. | 5 months ago | 939603 |
| 9. | ADAR1 Capital Management LLC | 5 months ago | 891183 |
| 10. | LAURION CAPITAL MANAGEMENT LP | 5 months ago | 867046 |
| 11. | Pathstone Holdings LLC | 5 months ago | 859110 |
| 12. | Hudson Bay Capital Management LP | 5 months ago | 725000 |
| 13. | Millennium Management LLC | 5 months ago | 584143 |
| 14. | Renaissance Technologies Corp | 5 months ago | 423100 |
| 15. | Two Sigma Advisers, LLC | 5 months ago | 421800 |
| 16. | Geode Capital Management, LLC | 5 months ago | 410206 |
| 17. | SG Americas Securities, LLC | 5 months ago | 401047 |
| 18. | Susquehanna International Group, LLP | 5 months ago | 373198 |
| 19. | Citadel Advisors Llc | 5 months ago | 345283 |
| 20. | Ikarian Capital, LLC | 5 months ago | 254312 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...